Healios K.K.: Clinical Trials

13 trials sponsored by Healios K.K., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 4 terminated, 1 unknown, 1 withdrawn. 9 Phase 2, 4 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 5, Terminated 2, Unknown 1, Withdrawn 1
Phase 14Completed 3, Terminated 1
Phase 33Terminated 2, Completed 1

Follow Healios K.K.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
MultiStem, Placebo - Trauma, Adult Stem Cells
Phase 2UnknownHealios K.K.1562020-11-092024-05-24
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
MultiStem, Placebo - ARDS
Phase 2 / Phase 3TerminatedHealios K.K.222020-04-282026-10-16
Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome
HLCM051 - Respiratory Distress Syndrome, Adult
Phase 2CompletedHealios K.K.352019-01-012024-01-17
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
MultiStem, Placebo - Ischemic Stroke
Phase 3TerminatedHealios K.K.2062018-07-282026-08-11
Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements
HLCM051, Placebo - Stroke, Acute
Phase 2 / Phase 3CompletedHealios K.K.2062017-11-152024-01-17
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome
MultiStem, Placebo - Acute Respiratory Distress Syndrome
Phase 1 / Phase 2CompletedHealios K.K.362016-01-012019-11-20
A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
AMI MultiStem cells, Sham - Heart Attack, NSTEMI
Phase 2TerminatedHealios K.K.342015-12-012021-07-22
Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation
MultiStem - Liver Transplantation
Phase 1TerminatedProf. Dr. Marc-H. Dahlke, Ph. D.32013-04-012018-08-17
Study to Examine the Effects of MultiStem in Ischemic Stroke
MultiStem, Placebo - Ischemic Stroke
Phase 2CompletedHealios K.K.1342011-10-012016-08-02
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis
placebo, MultiStem low dose, MultiStem high dose - Colitis, Ulcerative
Phase 2CompletedPfizer1052011-02-012016-02-23
A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety
ATHX-105 phosphate, Placebo - Obesity
Phase 2WithdrawnHealios K.K.2008-09-012015-06-02
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
MultiStem® - Hematologic Malignancies
Phase 1CompletedHealios K.K.362008-07-012012-01-05
Safety Study of AMI MultiStem® to Treat Heart Attacks
AMI MultiStem® - Acute Myocardial Infarction
Phase 1CompletedHealios K.K.252008-05-012012-05-11

Conditions studied

Ischemic Stroke (2)  ·  Myocardial Infarction (2)  ·  Respiratory Distress Syndrome (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Body Weight (1)  ·  COVID-19 (1)  ·  Colitis, Ulcerative (1)  ·  Dyspnea (1)  ·  Graft vs Host Disease (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia (1)  ·  Metabolic Diseases (1)  ·  Non-ST Elevated Myocardial Infarction (1)  ·  Nutrition Disorders (1)  ·  Obesity (1)

Interventions

salicylhydroxamic acid (1)

Countries

United States (9)  ·  Belgium (2)  ·  Germany (2)  ·  Japan (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  Hungary (1)  ·  Italy (1)  ·  Slovakia (1)  ·  Sweden (1)  ·  Taiwan (1)

Top investigators

Marc Penn, MD (2)  ·  Robert W Mays, PhD (2)  ·  Charles Cox, MD (1)  ·  Eric Jenkins, MD (1)  ·  Geoff Bellingan, MD (1)  ·  Hillard Lazarus, MD (1)  ·  Kazuya Ichikado, M.D., Ph.D. (1)  ·  Richard Maziarz, MD (1)  ·  Satoru Hashimoto, M.D., Ph.D. (1)  ·  Steven Devine, MD (1)  ·  Warren Sherman, MD (1)

Results publications

PMID 22052917, PMID 28320635, PMID 29134924, PMID 34811567, PMID 37608287, PMID 38227308

NIH funding

2009 (1), R44HL117572 (1)